Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Angina I: Introduction01:30

Angina I: Introduction

539
Definition and Symptoms: Angina (angina pectoris) is chest pain or discomfort caused by myocardial ischemia, which occurs when the heart muscle receives insufficient oxygen-rich blood. It typically manifests as pressing, squeezing, or crushing sensations in the chest and may radiate to the shoulders, arms, neck, jaw, or back.Primary Cause: In a healthy state, the coronary arteries can dilate (widen) to increase blood flow and meet the increased oxygen demand during physical activity or...
539
Angina II: Classification01:27

Angina II: Classification

399
Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
399
Angina IV: Management01:26

Angina IV: Management

294
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
294
Angina V: Nursing Management01:20

Angina V: Nursing Management

353
Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
353
Angina III: Clinical Manifestations and Assessment01:29

Angina III: Clinical Manifestations and Assessment

251
Angina manifests as chest pain, tightness, or squeezing discomfort typically located behind the breastbone. It can radiate to the neck, jaw, shoulders, and inner aspects of the upper arms, most commonly the left arm. Patients may experience shortness of breath, fatigue, profuse sweating, dizziness, indigestion, heartburn, palpitations, anxiety, and vomiting as accompanying symptoms. This pain often lasts a few minutes and is triggered by physical exertion, emotional stress, heavy meals, or cold...
251
Second Order systems II01:18

Second Order systems II

409
In an underdamped second-order system, where the damping ratio ζ is between 0 and 1, a unit-step input results in a transfer function that, when transformed using the inverse Laplace method, reveals the output response. The output exhibits a damped sinusoidal oscillation, and the difference between the input and output is termed the error signal. This error signal also demonstrates damped oscillatory behavior. Eventually, as the system reaches a steady state, the error diminishes to zero.
409

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stratified Medicine with Eplerenone for Myocardial Infarction or Injury and No obstructive Coronary Arteries: A Registry-Based Basket Trial.

American heart journal·2026
Same author

VEGF inhibitor-induced vascular dysfunction involves redox-sensitive PARP activation and SIRT1 disruption.

Experimental physiology·2026
Same author

Endotype-informed therapy and effects on illness perception and psychological health in patients with chest pain and no obstructive coronary artery disease.

European heart journal. Quality of care & clinical outcomes·2026
Same author

Recent advances in the pathophysiology of hypertension.

Physiology (Bethesda, Md.)·2026
Same author

Spike 1 protein of SARS-CoV-2 induces endothelial inflammation and vascular dysfunction through interferon ISG15-dependent mechanisms.

Cardiovascular research·2026
Same author

Non-invasive endotyping improves treatment satisfaction and prescribing appropriateness in patients with angina and no obstructive coronary artery disease.

Open heart·2026
Same journal

Great debate: medical treatment of heart failure with reduced ejection fraction will rely on four foundational drugs.

European heart journal·2026
Same journal

The surgical collateralization theory: has the beautiful hypothesis been killed by the ugly facts?

European heart journal·2026
Same journal

Beyond single measurement: additional considerations for high-sensitivity C-reactive protein in cardiovascular risk prediction.

European heart journal·2026
Same journal

Brain mineralocorticoid receptor activation and antagonism in heart failure with preserved ejection fraction: a hypothesis.

European heart journal·2026
Same journal

Myths and misconceptions about high-sensitivity C-reactive protein as a marker of residual inflammatory risk.

European heart journal·2026
Same journal

Vascular Ehlers-Danlos syndrome: should we treat asymptomatic patients?

European heart journal·2026
See all related articles

Related Experiment Video

Updated: Feb 5, 2026

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations
08:21

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations

Published on: July 21, 2023

2.1K

Systemic microvascular dysfunction in microvascular and vasospastic angina.

Thomas J Ford1,2,3, Paul Rocchiccioli1,2, Richard Good1

  • 1West of Scotland Heart and Lung Centre, Golden Jubilee National Hospital, GJNH, Agamemnon St, Glasgow, UK.

European Heart Journal
|August 31, 2018
PubMed
Summary
This summary is machine-generated.

Patients with microvascular angina (MVA) and vasospastic angina (VSA) exhibit systemic microvascular abnormalities. These conditions involve endothelial dysfunction and increased vasoconstriction, potentially linked to endothelin-1 (ET-1).

More Related Videos

Measurement of Myocardial Lactate Production for Diagnosis of Coronary Microvascular Spasm
06:18

Measurement of Myocardial Lactate Production for Diagnosis of Coronary Microvascular Spasm

Published on: September 17, 2021

1.9K
Author Spotlight: Advances in Quantifying Microvascular Density in Aging Murine Lungs
10:00

Author Spotlight: Advances in Quantifying Microvascular Density in Aging Murine Lungs

Published on: January 3, 2025

4.2K

Related Experiment Videos

Last Updated: Feb 5, 2026

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations
08:21

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations

Published on: July 21, 2023

2.1K
Measurement of Myocardial Lactate Production for Diagnosis of Coronary Microvascular Spasm
06:18

Measurement of Myocardial Lactate Production for Diagnosis of Coronary Microvascular Spasm

Published on: September 17, 2021

1.9K
Author Spotlight: Advances in Quantifying Microvascular Density in Aging Murine Lungs
10:00

Author Spotlight: Advances in Quantifying Microvascular Density in Aging Murine Lungs

Published on: January 3, 2025

4.2K

Area of Science:

  • Cardiovascular Research
  • Vascular Biology
  • Internal Medicine

Background:

  • Coronary microvascular dysfunction and vasospasm contribute to ischemia in patients with no obstructive coronary artery disease (INOCA).
  • The presence of peripheral small artery functional abnormalities in these patients remains to be fully elucidated.

Purpose of the Study:

  • To investigate whether patients with INOCA, specifically microvascular angina (MVA) and vasospastic angina (VSA), also exhibit functional abnormalities in peripheral small arteries.
  • To test the hypothesis of systemic microvascular dysfunction in INOCA patients.

Main Methods:

  • Prospective enrollment of patients categorized as MVA, VSA, or normal controls based on invasive coronary artery function tests.
  • Peripheral resistance arteries were isolated from gluteal subcutaneous fat biopsies for wire myography.
  • Assessment of endothelial function (acetylcholine) and endothelium-independent relaxation (sodium nitroprusside), as well as contractile responses to endothelin-1 (ET-1) and U46619.

Main Results:

  • Reduced maximum relaxation to acetylcholine (endothelial function) was observed in MVA and VSA patients compared to controls.
  • Increased contractile responses to endothelin-1 (ET-1) and U46619 were found in MVA patients versus controls.
  • Endothelium-independent relaxation was similar across all groups, while resistance arteries showed higher sensitivity to ET-1 compared to U46619.

Conclusions:

  • Systemic microvascular abnormalities are prevalent in patients diagnosed with MVA and VSA.
  • These abnormalities are characterized by endothelial dysfunction and enhanced vasoconstriction, with endothelin-1 (ET-1) implicated in the underlying mechanisms.